AbbVie stock: Q3 outlook raised as pipeline advances

Published on 11/07/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock enters the new week after stronger third-quarter growth lifted its 2026 outlook. New deals also broaden the drugmaker's pipeline.

AbbVie advances growth and pipeline

Third-quarter revenue increased 10.3 percent, prompting AbbVie to raise its 2026 adjusted earnings and revenue outlook.
A new Oxford research site expands work across immunology, neuroscience and oncology as part of more than GBP 120 million committed to UK life sciences.
An exclusive Nxera license gives AbbVie worldwide rights to develop and commercialize an investigational inflammatory bowel disease treatment.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie strengthened its investment case during the week ended Saturday, November 7, with stronger third-quarter results, a higher full-year outlook and two pipeline developments. The company reported the results on October 30, covering the quarter ended September 30, 2026.

According to AbbVie, third-quarter revenue rose 10.3 percent year over year to 17.4 billion US dollars. Adjusted earnings reached 3.82 US dollars per share. AbbVie lifted its 2026 adjusted diluted earnings guidance to 13.95 to 13.99 US dollars per share from 13.76 to 13.96 US dollars and raised its revenue outlook by 200 million US dollars to 67.8 billion US dollars.

The outlook includes an unfavorable 0.69 US dollar per-share impact from acquired in-process research and development and milestone expenses incurred through the third quarter. AbbVie said the guidance excludes similar expenses that may arise after the quarter.

Pipeline expansion adds strategic depth

AbbVie also signed an exclusive global license with Nxera for NXE0033744, an investigational EP4 receptor agonist for inflammatory bowel disease. The agreement includes a 100 million US dollar upfront payment and up to 1.37 billion US dollars in development and commercial milestones, plus tiered royalties. The transaction remains subject to customary antitrust clearances, according to Pharmaceutical Executive.

Separately, AbbVie expanded its Oxford research facility in the United Kingdom. The new 12,000-square-foot site supports research in immunology, neuroscience and oncology and forms part of more than 120 million pounds invested and committed across the UK life-sciences ecosystem, the company said in its Oxford announcement.

AbbVie stock traded at 260.65 euros on Lang & Schwarz at 11:20 CET on Saturday, November 7. Investors will weigh the raised outlook against research spending, milestone costs and the execution risk attached to early-stage pipeline assets. The real-time quote of AbbVie stock is available for ongoing monitoring.

US equities remain sensitive to expectations for earnings growth, healthcare demand and interest rates; see the S&P 500 market overview.

More developments can be found in more news and analyses on AbbVie stock.